KakaoTalk Consultation Naver Reservation

Evening Primrose Oil (Evoprim) · Borage Oil and Atopic Dermatitis | Research Findings


There is a medication I frequently see when atopic dermatitis patients show me prescriptions from other clinics. It is Evoprim, which contains evening primrose oil. Some patients also mention taking this along with borage oil as dietary supplements.

Evening primrose oil, Evoprim, and borage oil are all products that supplement gamma-linolenic acid. Among these, Evoprim is a pharmaceutical product covered by health insurance.

However, health insurance coverage does not guarantee efficacy, so I have compiled the research findings on gamma-linolenic acid and atopic dermatitis.

A single transparent yellow soft capsule placed in the center on a white background

Main Component of Evening Primrose Oil


The key component of evening primrose oil and borage oil is gamma-linolenic acid.

The exact biochemical pathway is more complex, but to explain it simply: our body has an enzyme called COX, which can produce either pro-inflammatory or anti-inflammatory substances depending on what raw material it receives. Aspirin suppresses inflammation precisely by inhibiting this COX enzyme.

Gamma-linolenic acid is a raw material that, when supplied to COX, produces anti-inflammatory substances. This led to the hypothesis that supplementing gamma-linolenic acid could reduce inflammation.1

A two-pathway diagram showing gamma-linolenic acid becoming a raw material for anti-inflammatory substances through the COX enzyme, while other fatty acids become raw materials for pro-inflammatory substances through the same COX enzyme

This hypothesis led to numerous studies.

Results of Comprehensive Analysis of Multiple Clinical Trials


However, in medicine, even excellent hypotheses often do not proceed as expected due to unforeseen variables. This is why observing actual effects through clinical trials is important.

The most frequently referenced source on the effects of evening primrose oil and borage oil for atopic dermatitis is the 2013 Cochrane study. Cochrane is an international nonprofit organization that conducts independent and objective medical research.

This study was not a single clinical trial, but rather a re-evaluation of data from 19 clinical trials on evening primrose oil and 8 clinical trials on borage oil, totaling 1,596 participants. Although it did not specifically examine pharmaceutical products like Evoprim, it is relevant reference material since Evoprim is the same formulation.2

The results were not clear. Neither the group taking evening primrose oil nor the group taking borage oil showed significant improvement in atopic dermatitis compared to placebo.2

Unfortunately, the conclusion has not changed significantly since then. An independent study published in 2025, unrelated to manufacturers, analyzed 13 clinical trials on evening primrose oil and concluded that there was no meaningful difference compared to placebo.3

Positive Studies


Of course, there are also positive studies.

Notable examples include a 1989 study that analyzed 9 studies related to an evening primrose oil product called Epogam, and a 2006 study that analyzed 26 studies related to a product called Efamol. Both papers concluded that symptoms such as itching, redness, and crusting could be reduced.4,5

There is also a Korean study. When 50 patients with mild atopic dermatitis took evening primrose oil for 4 months, their EASI scores improved more than the group taking placebo.6 EASI is an index that scores the extent and severity of atopic dermatitis. Detailed information is available in the EASI · SCORAD article.

However, the authors of the 2006 study are affiliated with a company called Wassen International, which acquired the manufacturer of Efamol.5 The Korean study states there is no conflict of interest, but the number of participants is quite small at 50.6 Therefore, it is difficult to give more weight to these positive studies than to the 2013 Cochrane study and the 2025 study introduced earlier.2,3

An illustration showing a tilted scale demonstrating that the weight of evidence from large-scale comprehensive analyses is greater than that of positive small-scale studies

Position of Evoprim in Atopic Dermatitis Treatment


Evoprim is a pharmaceutical product whose approved indication by the Ministry of Food and Drug Safety includes relief of itching due to atopic eczema, and it is covered by health insurance. A pediatric version of Evoprim is also approved as a separate product.7,8

However, consistent with the conclusions of the studies already introduced, and based on my clinical experience, Evoprim is not a medication I would actively recommend for atopic dermatitis.2,3 The same applies to evening primrose oil and borage oil.

The 2024 Korean Atopic Dermatitis Treatment Guidelines state that evening primrose oil can be used to a limited extent as an adjunctive therapy, and the European Academy of Allergy and Clinical Immunology report also states that the evidence for its efficacy is limited.9,10

Given the content of credible research findings and guidelines, it is advisable not to have excessive expectations for these three options.2,3,9,10


References


Which is better, evening primrose oil or borage oil?

u003cpu003eBoth are products that supplement gamma-linolenic acid. In the Cochrane analysis, neither evening primrose oil nor borage oil showed a clear difference from placebo in improving eczema symptoms. It is difficult to choose which is better.u003csupu003eu003ca href=u0022https://pubmed.ncbi.nlm.nih.gov/23633319/u0022 target=u0022_blanku0022 rel=u0022noopeneru0022 style=u0022color: inherit;u0022u003e2u003c/au003eu003c/supu003e u003c/pu003e

Can I take commercially available evening primrose oil dietary supplements instead of Evoprim?

u003cpu003eThe gamma-linolenic acid content varies by product. Evoprim is a product approved as a pharmaceutical, and commercially available evening primrose oil dietary supplements cannot be considered the same product. However, since Evoprim is not a medication with strongly proven efficacy, it is difficult to expect significant effects based solely on it being a pharmaceutical product.u003csupu003eu003ca href=u0022https://pubmed.ncbi.nlm.nih.gov/23633319/u0022 target=u0022_blanku0022 rel=u0022noopeneru0022 style=u0022color: inherit;u0022u003e2u003c/au003e,u003ca href=u0022https://pubmed.ncbi.nlm.nih.gov/38963342/u0022 target=u0022_blanku0022 rel=u0022noopeneru0022 style=u0022color: inherit;u0022u003e3u003c/au003eu003c/supu003e u003c/pu003e

Is it safe to give to children?

u003cpu003ePediatric Evoprim is a separate product for ages 1 to 12 and is covered by insurance. However, it should not be given to infants under 1 year of age, and it should be avoided if there is a soy or peanut allergy. Safety does not necessarily mean efficacy is certain.u003csupu003eu003ca href=u0022https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200301115u0022 target=u0022_blanku0022 rel=u0022noopeneru0022 style=u0022color: inherit;u0022u003e8u003c/au003eu003c/supu003e u003c/pu003e